Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan  Andreas Keil, Sean R. Hall, Meike Körner, Martin Herrmann, Ralph A. Schmid and Steffen Frese  Arthritis Research & Therapy, 2016 Oct 22. 18(1): 243    DOI: 10.1186/s13075-016-1144-5     

  The topoisomerase I inhibitor irinotecan and the tyrosyl-DNA phosphodiesterase 1 inhibitor furamidine synergistically suppress murine lupus nephritis  Andreas Keil, Manuela Frese-Schaper, Selina K. Steiner, Meike Körner, Ralph A. Schmid and Steffen Frese  Arthritis & Rheumatology, 2015 Mar 16. doi: 10.1002/art.39119

  Low-Dose Irinotecan Improves Advanced Lupus Nephritis in Mice Potentially by Changing DNA Relaxation and Anti–Double–Stranded DNA Binding  Manuela Frese-Schaper, Andreas Keil, Selina K. Steiner, Mathias Gugger, Meike Körner, Gregor J. Kocher, Lena Schiffer, Hans-Joachim Anders, Uyen Huynh-Do, Ralph A. Schmid and Steffen Frese  Arthritis & Rheumatology, Vol. 66, No. 8, August 2014, pp 2259–2269, DOI 10.1002/,   Supplement

   Structural modification of DNA – a therapeutic option in SLE?           Steffen Frese and Betty Diamond. Nature Reviews Rheumatology, Oct 18;7(12):733-8. doi: 10.1038/nrrheum.2011.153 -

  Reversal of Established Lupus Nephritis and Prolonged Survival of New Zealand Black 3 New Zealand White Mice Treated with the Topoisomerase I Inhibitor Irinotecan  Manuela Frese-Schaper, Jakob Zbaeren, Mathias Gugger, Marc Monestier, and Steffen Frese  The Journal of Immunology, February 15, 2010 Vol. 184 No. 4 2175-2182, DOI: 10.4049/​